Clinical Studies Search

Protocol Summary


Protocol No.
PSCI-20-081
Prinicipal Investigator
Joshi, Monika
Phase
Phase I
Age Group
Adult
Scope
National
Secondary Protocol No.
D7980C00003
Title
A phase 1b, Open-label Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Cell Carcinoma
Objective
Primary:
Determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of MEDI5752 combined with axitinib (Dose-exploration Phase) Assess safety and tolerability of MEDI5752
combined with axitinib.

Secondary:
Assess the antitumor activity of MEDI5752 combined with axitinib
Applicable Disease Sites
Kidney
Status
Open
Participating Institutions
Hershey Medical Center